Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib in Acute Leukemia and Myelodysplastic Syndrome
NCT00475150Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2008
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cediranib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by National Cancer Institute. Started May 2008; status: completed.
02
Drugs
cediranib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00475150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00475150.